[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100616126":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":18,"centralContacts":23,"locations":28,"responsibleParty":41,"collaborators":10,"id":43,"slug":44,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":45,"sex":51,"minAge":52,"maxAge":10,"enrollmentInfo":53,"targetDuration":10,"studyType":56,"phases":10,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":63,"whyStopped":10,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},{"fullName":5,"class":6},"Assistance Publique - Hôpitaux de Paris","OTHER",[8,12,15],{"label":9,"type":10,"description":11,"interventionNames":10},"groups 1: Craniopharyngioma patients",null,"40 adults surgically treated for craniopharyngioma (≥ 3 months post-surgery).",{"label":13,"type":10,"description":14,"interventionNames":10},"Control participants","80 adults without hypothalamic-pituitary disease, matched on age, sex, and BMI with groups 1 and 2.",{"label":16,"type":10,"description":17,"interventionNames":10},"groups 2: Pituitary macroadenoma patients","40 adults surgically treated for pituitary macroadenoma with ≥ 2 anterior pituitary hormone deficiencies.",[19],{"name":20,"affiliation":21,"role":22},"Mirella Hage, MD, PhD","Department of endocrinology, diabetology and nutrition, Ambroise Paré Hospital - A","PRINCIPAL_INVESTIGATOR",[24],{"name":20,"role":25,"phone":26,"phoneExt":10,"email":27},"CONTACT","+ 33 01 49 09 54 95","mirella.hage@aphp.fr",[29],{"facility":30,"status":10,"city":31,"state":10,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":10},"Department of endocrinology, diabetology and nutrition, Ambroise Paré Hospital - APHP","Boulogne-Billancourt","92100","France","FR",{"type":36,"coordinates":37},"Point",[38,39],2.24128,48.83545,{"lat":39,"lon":38},{"type":42,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100616126","food-preferences-and-craniopharyngiomas-100616126",false,"NCT07301554","Food Preferences and Craniopharyngiomas","Evaluation of Food Preferences in Patients Treated Surgically for Craniopharyngiomas","PREFAMHYPO","Inclusion Criteria:\n\n* Common inclusion criteria: complete medical record accessible, capacity to understand and complete self-administered questionnaires, agreement to complete the questionnaires at the time of inclusion, adult subject, not in an emergency situation, provision of non-opposition (opt-out consent documented), affiliation to a social security scheme.\n\nInclusion (Phase 1): Adults residing in France, aged 18 - 74 years from the general population.\n\nInclusion (Phase 2): Adults aged 18 - 74 years;\n\nGroup 1: patients with craniopharyngioma surgery ≥ 3 months prior to inclusion.\n\nGroup 2: patients with pituitary macroadenoma surgery with documented ≥ 2 anterior pituitary deficits.\n\nGroup 3: Follow-up for an endocrine condition without hypothalamo-hypophyseal involvement, acceptable conditions (thyroid nodule without dysthyroidism, PCOS, peripheral hirsutism, calcium metabolism disorders), no known treatments or prior medical history likely to influence eating behaviour.\n\nExclusion Criteria:\n\n* Common exclusion criteria: bariatric surgery, GLP-1 agonist treatment, chronic disease affecting alimentation, pregnancy or breastfeeding, specific diets (gluten-free, vegetarian, vegan...), refusal or opposition to data use, vulnerability status (under guardianship or legal protection) or inability to complete questionnaires or to understand the proposed research or to express a clear opinion regarding non-opposition.\n\nAdditional exclusion criteria:\n\nphase 1: Type 1 or type 2 diabetes, Active smoking, alcohol misuse, drug use, diagnosed psychiatric disorders or eating behaviour disorders.\n\nPhase 2:\n\nPerson benefiting from State Medical Aid (AME).\n\nControl group:\n\nHypothalamo-hypophyseal pathology, type 1 or type 2 diabetes, uncontrolled hyperthyroidism or hypothyroidism, adrenal hormone hypersecretion disorder, history of or ongoing treatment for active cancer.","ALL","18 Years",{"count":54,"type":55},346,"ESTIMATED","OBSERVATIONAL","The hypothalamus plays a key role in regulating appetite, satiety, and energy balance. When tumors such as craniopharyngiomas develop in this region, they can disrupt these mechanisms and lead to a form of severe weight gain known as hypothalamic obesity. Several factors play a role in the development of hypothalamic obesity that is often resistant to traditional treatments. Changes in food preferences notably a higher liking for food rich in fat and sugar may be implicated as has been reported in common obesity.\n\nThe working hypothesis of the study is that hypothalamic lesions may alter food preferences, leading to an increased preference for high-fat and high-sugar foods, and that these changes in dietary choices contribute among other factors to the development of hypothalamic obesity.\n\nBy providing the first evaluation of food preferences in adults treated surgically for craniopharyngiomas, this study will shed light on the role of hypothalamic lesions in modifying dietary choices. The results may help explain why some patients experience rapid and resistant weight gain, and could guide future strategies to better manage hypothalamic obesity.",[59],"Craniopharyngioma",[59,61,62],"food preferences","changes","NOT_YET_RECRUITING","2026-02-20",{"date":66,"type":67},"2026-02-23","ACTUAL",{"date":69,"type":55},"2026-02",{"date":71,"type":55},"2028-12",{"name":5,"class":6},1]